AMEX · TOVX
Healthcare · Biotechnology
$0.23
Up+$0.02 (+7.08%)
Updated Sep 17, 2026, 10:33 PM
SID Score
4.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
TOVX closed at $0.23 after 20 trading sessions, up 0.27% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 16, 2026 | $0.23 | $0.2316 | $0.2253 | $0.226 | 472.31K |
| Sep 15, 2026 | $0.237 | $0.2399 | $0.22 | $0.2251 | 548.44K |
| Sep 14, 2026 | $0.243 | $0.243 | $0.2356 | $0.2356 | 779.83K |
| Sep 11, 2026 | $0.2458 | $0.2479 | $0.2409 | $0.2476 | 344.42K |
| Sep 10, 2026 | $0.2446 | $0.2493 | $0.2426 | $0.2427 | 357.98K |
| Sep 9, 2026 | $0.2514 | $0.2514 | $0.2411 | $0.249 | 415.95K |
| Sep 8, 2026 | $0.2455 | $0.2533 | $0.2455 | $0.2471 | 377.58K |
| Sep 4, 2026 | $0.26 | $0.26 | $0.2483 | $0.253 | 431.52K |
| Sep 3, 2026 | $0.2513 | $0.2608 | $0.243 | $0.253 | 889.26K |
| Sep 2, 2026 | $0.248 | $0.2569 | $0.245 | $0.2481 | 419.3K |
| Sep 1, 2026 | $0.2571 | $0.2578 | $0.2402 | $0.249 | 516.31K |
| Aug 31, 2026 | $0.2427 | $0.2587 | $0.2427 | $0.25 | 300.13K |
| Aug 28, 2026 | $0.2522 | $0.2607 | $0.2431 | $0.2451 | 564.41K |
| Aug 27, 2026 | $0.2432 | $0.2621 | $0.235 | $0.2525 | 1.54M |
| Aug 26, 2026 | $0.2386 | $0.245 | $0.236 | $0.2432 | 438.4K |
| Aug 25, 2026 | $0.2452 | $0.2452 | $0.2375 | $0.2375 | 378.53K |
| Aug 24, 2026 | $0.2364 | $0.242 | $0.233 | $0.2351 | 365.72K |
| Aug 21, 2026 | $0.237 | $0.245 | $0.2313 | $0.235 | 521.67K |
| Aug 20, 2026 | $0.232 | $0.2377 | $0.2268 | $0.2302 | 413.28K |
| Aug 19, 2026 | $0.2244 | $0.2362 | $0.2244 | $0.2254 | 807.53K |
The latest Smart Investors Daily articles mentioning TOVX.
TOVX research
Company profile and research snapshot.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 31, 2026 | Maxim Group | Buy | — |
| May 8, 2025 | Maxim Group | Hold | — |
| Nov 13, 2024 | Maxim Group | Buy | — |
No generated briefing is available yet.
ChartMill · Aug 14, 2026
As the regular session of the US market on Friday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.
Benzinga · Aug 11, 2026
Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 96.37 percent increase over losses of $(1.93) per share from
Benzinga · Jul 7, 2026
Trial is entitled "A Phase IIa, single-arm, single-center, open-label, proof-of-concept trial evaluating increased frequency dosing of zabilugene almadenorepvec (VCN-01) in combination with
Benzinga · Jun 11, 2026
– Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab ––
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning TOVX.
